These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 24013384)

  • 1. Post-marketing study on the safety of a meningococcal group A, C bivalent polysaccharide conjugate vaccine.
    Fu C; Huang G; Cui M; Wang M
    Hum Vaccin Immunother; 2014; 10(1):138-9. PubMed ID: 24013384
    [No Abstract]   [Full Text] [Related]  

  • 2. [Evaluation of safety of meningococcal group AC bivalent polysaccharide conjugate vaccine in children aged 5-24 months old].
    Zhou H; Wang JY; Tan Y; Lü HY; Wang M; Cai QC; Zhang HZ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2013 Oct; 47(10):920-3. PubMed ID: 24378132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2-10 years: a phase II/III double-blind randomized controlled trial.
    Hirve S; Bavdekar A; Pandit A; Juvekar S; Patil M; Preziosi MP; Tang Y; Marchetti E; Martellet L; Findlow H; Elie C; Parulekar V; Plikaytis B; Borrow R; Carlone G; Kulkarni PS; Goel A; Suresh K; Beri S; Kapre S; Jadhav S; Preaud JM; Viviani S; LaForce FM
    Vaccine; 2012 Oct; 30(45):6456-60. PubMed ID: 22898557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Safety of PsA-TT in Pregnancy: An Assessment Performed Within the Navrongo Health and Demographic Surveillance Site in Ghana.
    Wak G; Williams J; Oduro A; Maure C; Zuber PL; Black S
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S489-92. PubMed ID: 26553679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of MenACWY-TT, a meningococcal conjugate vaccine, co-administered with routine childhood vaccine in healthy infants: A phase III, randomized study.
    Dbaibo G; Tinoco Favila JC; Traskine M; Jastorff A; Van der Wielen M
    Vaccine; 2018 Jun; 36(28):4102-4111. PubMed ID: 29784470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-marketing safety monitoring of a new group B meningococcal vaccine in New Zealand, 2004-2006.
    McNicholas A; Galloway Y; Stehr-Green P; Reid S; Radke S; Sexton K; Kieft C; Macdonald C; Neutze J; Drake R; Isaac D; O'Donnell M; Tatley M; Oster P; O'Hallahan J
    Hum Vaccin; 2007; 3(5):196-204. PubMed ID: 17660718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase 3, Double-Blind, Randomized, Active Controlled Study to Evaluate the Safety of MenAfriVac in Healthy Malians.
    Tapia MD; Sow SO; Haidara FC; Diallo F; Doumbia M; Enwere GC; Paranjape G; Hervé J; Bouma E; Parulekar V; Martellet L; Chaumont J; Plikaytis BD; Tang Y; Kulkarni PS; Hartmann K; Preziosi MP
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S507-13. PubMed ID: 26553682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody responses to meningococcal (groups A, C, Y and W135) polysaccharide diphtheria toxoid conjugate vaccine in children who previously received meningococcal C conjugate vaccine.
    El Bashir H; Heath PT; Papa T; Ruggeberg JU; Johnson N; Sinha R; Balfour G; Booy R
    Vaccine; 2006 Mar; 24(14):2544-9. PubMed ID: 16417952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy, safety, and cost-effectiveness of meningococcal vaccines].
    Chinese Preventive Medicine Association
    Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Feb; 40(2):129-135. PubMed ID: 30744260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Active Surveillance for Adverse Events After a Mass Vaccination Campaign With a Group A Meningococcal Conjugate Vaccine (PsA-TT) in Mali.
    Vannice KS; Keita M; Sow SO; Durbin AP; Omer SB; Moulton LH; Yaméogo TM; Zuber PL; Onwuchekwa U; Sacko M; Diomandé FV; Halsey NA
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S493-500. PubMed ID: 26553680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meningococcal polysaccharide A O-acetylation levels do not impact the immunogenicity of the quadrivalent meningococcal tetanus toxoid conjugate vaccine: results from a randomized, controlled phase III study of healthy adults aged 18 to 25 years.
    Lupisan S; Limkittikul K; Sosa N; Chanthavanich P; Bianco V; Baine Y; Van der Wielen M; Miller JM
    Clin Vaccine Immunol; 2013 Oct; 20(10):1499-507. PubMed ID: 23885033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statement on conjugate meningococcal vaccine for serogroups A, C, Y and W135. An Advisory Committee Statement (ACS).
    National Advisory Committee on Immunization (NACI)
    Can Commun Dis Rep; 2007 May; 33(ACS-3):1-23. PubMed ID: 17520774
    [No Abstract]   [Full Text] [Related]  

  • 13. An evaluation of the immunogenicity and safety of a new trivalent meningococcal polysaccharide vaccine.
    Chandramohan D; Hodgson A; Coleman P; Baiden R; Asante K; Awine E; Owusu-Agyei S; Boutriau D; Nelson CB; Greenwood B
    Vaccine; 2007 Sep; 25 Suppl 1():A83-91. PubMed ID: 17521782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MenACWY-D) in infants and children.
    Hansen J; Zhang L; Eaton A; Baxter R; Robertson CA; Decker MD; Greenberg DP; Bassily E; Klein NP
    Vaccine; 2018 Apr; 36(16):2133-2138. PubMed ID: 29550195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of a meningococcal quadrivalent conjugate vaccine in Saudi Arabian adolescents previously vaccinated with one dose of bivalent and quadrivalent meningococcal polysaccharide vaccines: a phase III, controlled, randomized, and modified blind-observer study.
    Al-Mazrou Y; Khalil M; Findlow H; Chadha H; Bosch Castells V; Johnson DR; Borrow R
    Clin Vaccine Immunol; 2012 Jul; 19(7):999-1004. PubMed ID: 22552602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of the 4CMenB and MenACWY-CRM meningococcal vaccines administered concomitantly in infants: A phase 3b, randomized controlled trial.
    Macias Parra M; Gentile A; Vazquez Narvaez JA; Capdevila A; Minguez A; Carrascal M; Willemsen A; Bhusal C; Toneatto D
    Vaccine; 2018 Nov; 36(50):7609-7617. PubMed ID: 30414782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of meningococcal ACWY CRM197-conjugate vaccine in children, adolescents and adults in Russia.
    Ilyina N; Kharit S; Namazova-Baranova L; Asatryan A; Benashvili M; Tkhostova E; Bhusal C; Arora AK
    Hum Vaccin Immunother; 2014; 10(8):2471-81. PubMed ID: 25424958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: a systematic review and meta-analysis.
    Flacco ME; Manzoli L; Rosso A; Marzuillo C; Bergamini M; Stefanati A; Cultrera R; Villari P; Ricciardi W; Ioannidis JPA; Contopoulos-Ioannidis DG
    Lancet Infect Dis; 2018 Apr; 18(4):461-472. PubMed ID: 29371070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine.
    Dbaibo G; Van der Wielen M; Reda M; Medlej F; Tabet C; Boutriau D; Sumbul A; Anis S; Miller JM
    Int J Infect Dis; 2012 Aug; 16(8):e608-15. PubMed ID: 22704725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of a trivalent serogroup A/C/W135 meningococcal polysaccharide vaccine in Burkina Faso, 2003.
    Soriano-Gabarró M; Toé L; Tiendrebeogo SR; Nelson CB; Dabal M; Djingarey MH; Plikaytis B; Rosenstein N;
    Vaccine; 2007 Sep; 25 Suppl 1():A92-6. PubMed ID: 17517451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.